Dr. Reddy’s Laboratories is claiming eligibility for 180 days of market exclusivity for two strengths of generic Revlimid (lenalidomide) with a US Food and Drug Administration approval, after Natco Pharma and partners Arrow and Teva bagged the first generic approval earlier this year for the blockbuster treatment for multiple myeloma.
The Indian firm has obtained final approval for its abbreviated new drug application referencing Revlimid capsules in 2.5mg and 20mg...




